| Aplastic Anemia and MDS International Foundation

Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation

This multicenter study, which began in 2013, was led by Dr. Eytan Stein at Memorial Sloan Kettering Cancer Center in New York, NY. Its purpose was to evaluate the safety and efficacy of orally administered AG-221 (Enasidenib) in subjects with advanced Acute Myeloid Leukemia (AML) that harbor an IDH2